VANCOUVER, British Columbia — Anti-VEGF treatment did not improve vision in patients with fovea-involved macular atrophy, according to a poster presented at the Association for Research in Vision and Ophthalmology meeting.
“In patients with macular atrophy that involves the fovea at baseline, anti-VEGF does not lead to visual recovery over 3 years,” author Weilin Song, BS, told Healio.com/OSN.
Song, from Case Western Reserve University School of Medicine and Cole Eye Institute, Cleveland, and colleagues undertook the study to investigate the variability in response to
Uncategorized